Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Pfizer and BioNTech Advance COVID-19 Vaccine Strategy on Enhanced Spike Protein Design

    Pfizer Inc and BioNTech SE announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to evaluate the safety, tolerability, and immune response of an enhanced COVID-19 mRNA-based vaccine candidate at a 30 µg dose level. This next-generation bivalent COVID-19 vaccine candidate, BNT162b5, consists of RNAs encoding enhanced prefusion spike proteins for the SARS-CoV-2 ancestral strain (wild-type) and an Omicron variant.

  • FDA Details Optimized Approach for Regulatory Oversight Tools to Better Protect Public Health

    The U.S. Food and Drug Administration prioritizes the health and safety of American consumers and patients as well as animals and uses a variety of tools for the appropriate oversight of FDA-regulated products and establishments. With manufacturers and supply chains dispersed around the world, the FDA works to help ensure that only products that meet our rigorous standards reach the U.S. marketplace.

  • Colorectal cancer tumors both helped and hindered by T cells

    Colorectal tumors are swarming with white blood cells, but whether these cells help or hinder the cancer is hotly debated. While some studies have shown that white blood cells heroically restrict tumor growth and combat colorectal cancer, equally compelling evidence casts the white blood cells as malignant co-conspirators bolstering the tumor and helping it spread.

  • NATCO Announces Approval of its ANDA for Cabazitaxel Intravenous Solution

    Natco Pharma Limitedannounces that the U.S. Food and Drug Administration has granted approval to its partner Breckenridge Pharmaceutical Inc’s Abbreviated New Drug Application for Cabazitaxel Intravenous Powder (generic for Jevtana Kit) for the 60mg/1.5mL (40mg/mL) strength.

  • Cosmohome Tech Expo 2022

    Cosmohome Tech Expo was held in Delhi at Pragati Maidan on 14th & 15th July 2022. Cosmohome Tech Expo is South Asia’s largest manufacturing trade show for the Cosmetic, Personal care, Cosmeceutical, Perfumery & Soap, detergent, and toiletries market. It is conceptualized on bringing the complete Innovative solutions to the beauty manufacturers right from the concept to formulation to technology to product launch for making the advancements in the manufacturing world.

  • Drugs and Cosmetics Act, 1940 to be replaced by Drugs, Medical Devices and Cosmetics Bill, 2022

    The old Drugs and Cosmetics Act, 1940 is to be replaced by the New Drugs, Medical Devices and Cosmetics Bill, 2022. Ministry of Health and Family Welfare, Government of India proposes a draft New Drugs, Medical Devices and Cosmetics Bill, 2022 in order to keep pace with changing needs, times, technology.

  • Dr. Reddys Laboratories announces the launch of Fesoterodine Fumarate Extended-Release Tablets in the U.S. market

    Dr. Reddys Laboratories Ltd is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

  • Lupin Somerset Manufacturing Plant Receives EIR from USFDA

    Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

  • How Omicron dodges the immune system

    The current wave of COVID-19 highlights a particularly high risk of reinfection by the Omicron variant of SARS-CoV-2. Why is this? A team from the Centre for Emerging Viral Diseases of the University of Geneva (UNIGE) and of the Geneva University Hospital (HUG) analysed the antibody neutralisation capacity of 120 people infected with the original SARS-CoV-2 strain, or with one of its Alpha, Beta, Gamma, Delta, Zeta or Omicron (sub-variant BA.1) variants.

  • Pharma companies to share data on antimicrobial resistance

    The initiative launched last month (21 June) by Vivli, a non-profit clinical research data sharing organisation, will enable scientists from all over the world to access data on epidemiological, physical and genetic characteristics of organisms and their resistance to various antibiotics.

Subscribe to Pharma News